DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neoplasm Metastasis

Intervention: Radium-223 dichloride (BAY88-8223) (Radiation)

Phase: Phase 1

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

A new bone-seeking radiopharmaceutical drug, called Radium-223 dichloride (formerly known as "Alpharadin"), is currently under development. It is an injectable aqueous solution containing radium-223, a radionuclide that emits radiation of another quality and with a different distribution than radiopharmaceuticals currently in use. After injection of the drug into the blood, a large portion of the drug will accumulate in the bones, and irradiate the skeletal metastases. The drug is expected to be retained longer in the painful sites of bone than in other sites of the body, and may alleviate pain through its radiation. Radium-223 is expected to be both efficacious as regards the targeted localised irradiation, and also to have a favourable safety profile. The radiopharmaceutical drug Radium-223 has not been given to humans before. In this first clinical study in man, a so-called phase I study, the safety, tolerance and the toxicity of various radioactivity doses of Radium-223 will be evaluated.

Clinical Details

Official title: A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Number of participants with predetermined adverse events (dose limiting toxicity [DLT]) as a measure of safety and tolerability while dose escalating

Secondary outcome:

Blood clearance of radioactivity

Quality of Life Questionnaire

Eligibility

Minimum age: 30 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- ≥ 30 years of age

- has histologically or cytologically confirmed breast or prostate carcinoma

- presents with bony metastases, confirmed by scintigraphic imaging within the previous

4 weeks

- relapsing with new foci in the skeleton after previous external radiotherapy

- has a life expectancy of at least 8 weeks (study part Ia), 5 months for study part Ib

- good performance status; ECOG (Eastern Cooperative Oncology Group) status 0-2

- has normal bone marrow, hepatic, renal and cardiac functions

- clinical chemical laboratory values are within pre-specified range, measured within 7

days prior to dosing day

- for female patients: post-menopausal, surgically sterile or taking adequate

contraceptive precaution Exclusion Criteria:

- has previously been included in this study. This criterion is applicable for patients

that receive a single injection of the study drug, but not for patients to be re-treated, or for those to receive a fractionated dosing regimen (study part Ib).

- has received an investigational drug in the 4 weeks before or is scheduled to

receiving one during or in the 8 weeks after study drug administration. This criterion is applicable for patients that receive a single injection of the study drug and for patients to be re-treated.

- has received any other investigational drug than radium-223 in the 4 weeks before

first injection of study drug or is scheduled to receiving one during or in the 8 weeks after the fractionated study drug regimen. This criterion is applicable for patients receiving fractionated dose of the study drug.

- has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry

in the study

- has other active, serious, life-threatening disease with a life expectancy of less

than 8 weeks

- has any uncontrolled infection

- requires oxygen for pulmonary metastases

- has poor renal function with S-Creatinine >150 mmol/L (males), >100 mmol/L (females)

- has heart insufficiency, Class III or IV NYHA (New York Heart Association)

- is pregnant or lactating

- for female patients: of childbearing potential, and not taking adequate contraceptive

measures

Locations and Contacts

Oslo, Norway

Tromsoe, Norway

Stockholm, Sweden

Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: August 2001
Last updated: February 22, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017